Back to top

Image: Bigstock

Here's Why You Should Invest in athenahealth (ATHN) Now

Read MoreHide Full Article

athenahealth, Inc. is currently one of the top performing stocks in the MedTech space. The company’s focus on big-data and a raised guidance for 2018 makes it a lucrative investment pick.

Shares Up

Year to date, shares of athenahealth have rallied 14.4% compared with the industry’s 11.9% rise. The current level is also higher than the S&P 500 index’s return of 8.8%.

This Zacks Rank #1 (Strong Buy) stock currently has a Growth Score of A. This reflects possibilities of outperformance over the long haul. Our research shows that stocks, with a Growth Score of A or B, when combined with a Zacks Rank #1 or 2 (Buy), are better picks than most.

Which Way Are Estimates Treading?

For the current quarter, the Zacks Consensus Estimate for earnings per share is pegged at 98 cents, reflecting year-over-year growth of 75%. The same for revenues stands at $336.4 million, showing growth of 10.4% year over year.

For the current year, the Zacks Consensus Estimate for earnings per share is pinned at $4.17, showing growth of 68.2% over the last year. The same for revenues stands at $1.35 billion, showing growth of 10.4% from last year.

athenahealth, Inc. Price and Consensus


athenahealth, Inc. Price and Consensus | athenahealth, Inc. Quote

Let’s delve deeper.

Factors That Make It an Attractive Pick

Focus on Cloud-Based Services

athenahealth is a key player in the HCIT (Healthcare IT) space. The company’s cloud-based big data network — athenaNet — deserves a special mention here. Per management, there are nearly 116,000 providers on athenaNet currently.

Other notable platforms include athenaClinicals, the company’s first economically sustainable, service-based electronic medical records (EMR) system and athenaCollector. In the last reported quarter, the number of athenaCollector providers increased 15% year over year.

Guidance Raised

For 2018, athenahealth expects revenues in the range of $1.34-$1.37 billion, up from the previous guidance of $1.31-$1.38 billion.

The company expects adjusted operating income in the range of $244-$270 million, up from previous guidance of $210-$235 million.

Adjusted operating margin is expected in the band of 18.3-19.8% of net revenues for 2018, up from the previous guidance of 16-17%.

Other Key Picks

Some other top-ranked stocks in the broader medical space are Intuitive Surgical (ISRG - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Masimo Corporation (MASI - Free Report) .

Intuitive Surgical’s expected long-term earnings growth rate is 14.7%. The stock sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Integer Holdings has an expected growth rate of 12.6% for the next year. The stock carries a Zacks Rank #2.

Masimo’s long-term earnings growth rate is projected at 14.8%. The stock carries a Zacks Rank #2.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Masimo Corporation (MASI) - free report >>

Integer Holdings Corporation (ITGR) - free report >>

Intuitive Surgical, Inc. (ISRG) - free report >>

Published in